Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience-Reference-Cited by-同舟云学术

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

Published:2018-04-26 Issue:17 Volume:131 Page:1910-1919
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

O’Brien Susan¹²,Furman Richard R.³,Coutre Steven⁴,Flinn Ian W.⁵,Burger Jan A.¹,Blum Kristie⁶,Sharman Jeff⁷,Wierda William¹,Jones Jeffrey⁶,Zhao Weiqiang⁶,Heerema Nyla A.⁶,Johnson Amy J.⁶,Luan Ying⁸,James Danelle F.⁸,Chu Alvina D.⁸,Byrd John C.⁶

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA;

3. Department of Medicine, Weill Cornell Medical College, New York, NY;

4. Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA;

5. Sarah Cannon Research Institute, Nashville, TN;

6. The Ohio State University Comprehensive Cancer Center, Columbus, OH;

7. Willamette Valley Cancer Institute and Research Center, Springfield, OR; and

8. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA

Abstract

Key Points Our 5-year experience shows sustained single-agent efficacy of ibrutinib in CLL patients, with complete response rates increasing over time. Long-term ibrutinib was well tolerated with no new safety signals; rates of grade ≥3 cytopenias decreased with continued therapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/17/1910/1406283/blood810044.pdf

Reference27 articles.

1. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial;Catovsky;Lancet,2007

2. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997;Flinn;J Clin Oncol,2007

3. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

4. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial;Fischer;Blood,2016

5. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia;Keating;J Clin Oncol,2005

Cited by 330 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study;2024-01-03

2. Chimeric Antigen Receptor T-cell Therapy for Chronic Lymphocytic Leukemia: What is the supporting evidence so far?;Clinical Hematology International;2023-11-28

3. First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma;Cancer Discovery;2023-11-06

4. Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: a single-center retrospective analysis;Clinical and Experimental Medicine;2023-11-04

5. Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma;The European Research Journal;2023-11-04